Skip to content

H.R. 7867 · 119th Congress (2025–2027)

Infant Formula Safety Modernization Act of 2026

This bill directs the Food and Drug Administration (FDA) to expand requirements for the testing of infant formula and formula manufacturing facilities for pathogens and microorganisms.

Current regulations generally require manufacturers to test finished formula products for Cronobacter and Salmonella. The FDA tests manufacturing facilities for these contaminants in regular inspections, but manufacturers are not required to test their own facilities.

Within 90 days of the bill's enactment, the FDA must issue a final rule requiring manufacturers to test their facilities and finished formula products for certain pathogens and microorganisms, including Clostridium botulinum (which causes botulism). These regulations must include a recommended frequency for facilities testing, including requirements for testing different areas based on their proximity to formula products.

Manufacturers must notify the FDA within one business day of any positive result for one of the specified pathogens or microorganisms in a finished formula product, even if the product is still in the manufacturer’s possession. (Currently, notice is required only if the affected product has left the manufacturer’s facilities.) Manufacturers must also retain records of any positive result (from a test of formula or facilities).

The FDA must notify Congress within one business day of

  • receiving notice of a positive test result for a finished formula product, or
  • recommending official corrective action to address the findings of a facility inspection.

Finally, the regulations must explicitly require the FDA to enforce consistent inspection and compliance standards for all formula products, including imported products.

Show official title

To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 7867’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Rosa L. DeLauro (D-CT-3)
Cosponsors
47 cosponsors

17 original · 30 later

4 R · 43 D

  1. Rep. Sanford D. Bishop, Jr. (D-GA-2)· Original · Mar 9, 2026
  2. Rep. Steve Cohen (D-TN-9)· Original · Mar 9, 2026
  3. Rep. Madeleine Dean (D-PA-4)· Original · Mar 9, 2026
  4. Rep. Adelita S. Grijalva (D-AZ-7)· Original · Mar 9, 2026
  5. Rep. Sara Jacobs (D-CA-51)· Original · Mar 9, 2026
  6. Rep. Raja Krishnamoorthi (D-IL-8)· Original · Mar 9, 2026
  7. Del. Eleanor Holmes Norton (D-DC)· Original · Mar 9, 2026
  8. Rep. Jimmy Panetta (D-CA-19)· Original · Mar 9, 2026
  9. Rep. Chris Pappas (D-NH-1)· Original · Mar 9, 2026
  10. Rep. Mike Quigley (D-IL-5)· Original · Mar 9, 2026
  11. Rep. Deborah K. Ross (D-NC-2)· Original · Mar 9, 2026
  12. Rep. Janice D. Schakowsky (D-IL-9)· Original · Mar 9, 2026
  13. Rep. Rashida Tlaib (D-MI-12)· Original · Mar 9, 2026
  14. Rep. Shri Thanedar (D-MI-13)· Original · Mar 9, 2026
  15. Rep. Jefferson Van Drew (R-NJ-2)· Original · Mar 9, 2026
  16. Rep. Nikema Williams (D-GA-5)· Original · Mar 9, 2026
  17. Rep. Frederica S. Wilson (D-FL-24)· Original · Mar 9, 2026
  18. Rep. Grace Meng (D-NY-6)· Later · Mar 18, 2026
  19. Rep. André Carson (D-IN-7)· Later · Apr 13, 2026
  20. Rep. Seth Magaziner (D-RI-2)· Later · Apr 20, 2026
  21. Rep. Ayanna Pressley (D-MA-7)· Later · Apr 27, 2026
  22. Rep. Julia Brownley (D-CA-26)· Later · May 12, 2026
  23. Rep. Lori Trahan (D-MA-3)· Later · May 12, 2026
  24. Rep. Jesús G. "Chuy" García (D-IL-4)· Later · May 20, 2026
  25. Rep. Melanie A. Stansbury (D-NM-1)· Later · May 20, 2026
  26. Rep. Michael Lawler (R-NY-17)· Later · Jun 22, 2026
  27. Rep. Seth Moulton (D-MA-6)· Later · Jun 22, 2026
  28. Rep. Debbie Wasserman Schultz (D-FL-25)· Later · Jul 13, 2026
  29. Rep. Suzanne Bonamici (D-OR-1)· Later · Jul 16, 2026
  30. Rep. Ted Lieu (D-CA-36)· Later · Jul 16, 2026
  31. Rep. LaMonica McIver (D-NJ-10)· Later · Jul 20, 2026
  32. Rep. Danny K. Davis (D-IL-7)· Later · Jul 21, 2026
  33. Rep. Jonathan L. Jackson (D-IL-1)· Later · Jul 21, 2026
  34. Rep. Teresa Leger Fernandez (D-NM-3)· Later · Jul 21, 2026
  35. Rep. Greg Landsman (D-OH-1)· Later · Jul 21, 2026
  36. Rep. Jamie Raskin (D-MD-8)· Later · Jul 21, 2026
  37. Rep. Robin L. Kelly (D-IL-2)· Later · Jul 22, 2026
  38. Rep. Betty McCollum (D-MN-4)· Later · Jul 22, 2026
  39. Rep. Suzan K. DelBene (D-WA-1)· Later · Aug 24, 2026
  40. Rep. Sarah Elfreth (D-MD-3)· Later · Aug 24, 2026
  41. Rep. Henry C. "Hank" Johnson, Jr. (D-GA-4)· Later · Aug 24, 2026
  42. Rep. Riley M. Moore (R-WV-2)· Later · Aug 24, 2026
  43. Rep. Eugene Simon Vindman (D-VA-7)· Later · Aug 24, 2026
  44. Rep. Brian K. Fitzpatrick (R-PA-1)· Later · Sep 10, 2026
  45. Rep. Christopher R. Deluzio (D-PA-17)· Later · Oct 22, 2026
  46. Rep. Mark DeSaulnier (D-CA-10)· Later · Oct 22, 2026
  47. Rep. Laura Friedman (D-CA-30)· Later · Oct 26, 2026
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    Sources

Committees

  1. HouseEnergy and CommerceReferred Mar 9, 2026

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Infant Formula Safety Modernization Act of 2026

    Display title, Short title · Introduced in House

  2. To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.

    Official title · Introduced in House